Riccardo Lobefaro

8PUBLICATIONS
39CO-AUTHORS
Tumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer cell biologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 31, 2024
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer.

Davide Massa, Claudio Vernieri, Lorenzo Nicolè

|Aug 03, 2023
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation.

Sara Lonardi, Cosimo Rasola, Riccardo Lobefaro

|Sep 01, 2022
Circulating biomarkers in malignant pleural mesothelioma.

Giuseppe Viscardi, Davide Di Natale, Morena Fasano

|May 05, 2021
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients.

Francesca Ligorio, Luca Zambelli, Achille Bottiglieri

|Dec 18, 2020
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis.

Riccardo Lobefaro, Emma Zattarin, Federico Nichetti

|Dec 15, 2020
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications.

Emma Zattarin, Rita Leporati, Francesca Ligorio

Pageof 2

Frequent Collaborators

2 joint publications

Achille Bottiglieri

2 joint publications

Andrea Vingiani

2 joint publications

Claudio Vernieri

2 joint publications

Matteo Fassan